Woo J, Propper D J, Thomson A W
Department of Pathology, University of Aberdeen, U.K.
Immunology. 1990 Dec;71(4):551-5.
The novel macrolide immunosuppressant FK-506 demonstrated superior potency to cyclosporin A (CsA) in the inhibition of purified protein derivative (PPD)-induced human T-cell proliferation. Pulsing of monocytes with PPD for 24 hr in the presence of FK-506 did not impair their capacity to subsequently induced the proliferation of purified autologous T cells. In contrast, FK-506 profoundly inhibited the proliferative response of T cells to antigen-pulsed monocytes. Recombinant IL-2, but not IL-1, partially restored the proliferative response to PPD in the presence of the drug. FK-506 had no effect on basal or rIFN-gamma-induced expression of HLA-DR on monocytic cell line cells. These findings provide the first evidence that FK-506 can profoundly inhibit soluble antigen-induced human T-cell proliferation at concentrations which do not significantly impair the accessory function of mononuclear phagocytes.
新型大环内酯类免疫抑制剂FK-506在抑制纯化蛋白衍生物（PPD）诱导的人T细胞增殖方面表现出比环孢素A（CsA）更强的效力。在FK-506存在的情况下，用PPD刺激单核细胞24小时并不损害其随后诱导纯化的自体T细胞增殖的能力。相比之下，FK-506显著抑制T细胞对抗原刺激的单核细胞的增殖反应。在药物存在的情况下，重组IL-2而非IL-1部分恢复了对PPD的增殖反应。FK-506对单核细胞系细胞上HLA-DR的基础表达或rIFN-γ诱导的表达没有影响。这些发现首次证明，FK-506在不显著损害单核吞噬细胞辅助功能的浓度下，能够显著抑制可溶性抗原诱导的人T细胞增殖。
